siltuximab + docetaxel

A combination of **siltuximab**, a chimeric monoclonal antibody targeting interleukin-6 (IL-6), and **docetaxel**, a small-molecule antineoplastic in the taxane class. Siltuximab binds to IL-6, preventing its interaction with both soluble and membrane-bound IL-6 receptors, thus inhibiting IL-6-mediated signaling. Docetaxel stabilizes microtubules, inhibiting cell division and leading to cancer cell apoptosis. This combination has been explored in clinical studies for **castration-resistant prostate cancer (CRPC)**, showing safety, pharmacokinetic compatibility, and evidence of preliminary efficacy such as PSA declines and partial radiographic responses, though toxicity, especially myelosuppression, is notable. Both agents are approved as single agents for other indications, but this specific combination is **investigational**[1][2][3].

Other names

siltuximab + docetaxel